Pharma Industry News

Vitrakvi deemed ‘not cost-effective’ by NICE

The organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]